Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208883> ?p ?o ?g. }
- W4387208883 endingPage "e203" @default.
- W4387208883 startingPage "e203" @default.
- W4387208883 abstract "We report on our early experience of a multi-institutional phase II study of dose escalated five fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer after partial mastectomy using the GammaPodTM stereotactic radiation system.Patient eligibility included DCIS or invasive epithelial histologies, AJCC clinical stage 0, I, or II with tumor size < 3 cm, and negative margins. Prior safety of Phase I dose escalation has been reported. Dose was 40 Gy delivered in 5 fractions to the CTV, and minimum dose 30 Gy in 5 fractions to the PTV. CTV margin was 1 cm and PTV margin 3 mm. For PTV cavities larger than 100cc, dose was reduced to 35Gy in 5 fractions to the CTV and 30 Gy in 5 fractions to the PTV. Primary endpoint of the study is to determine the 3-year patient global cosmesis score (4-point scale excellent, good, fair, or poor) and adverse cosmesis using a dose escalated approach with smaller PTV margins than conventional methods. Both patients and physicians completed baseline and subsequent cosmesis outcome questionnaires. Treatment related toxicity was graded using the NCI version 4.0 and RTOG/EORTC late radiation scale.From 3/2019-10/2021, 74 patients were treated respectively. Of these, 38 were treated to 40Gy and 36 were treated to 35 Gy. Median follow up (f/u) was 24 months (mo), range (r) 3-39mo. Median age was 63 years (r 43-77). Histology included 28 DCIS, and 46 invasive carcinomas. 45/46 invasive tumors were ER+. 60/74 (81%) patients received endocrine therapy, and 7/74 patient received chemotherapy. There were 221 acute grade 1 toxicities, and 28 Grade 2 toxicities. No grade 3 or higher acute toxicities were reported (< 90 days). The most common Grade 2 toxicities were radiation dermatitis (10), breast pain (8), blister (4), skin infection (2), nipple discharge (2), and fatigue (2). In the late period, there were 54 Grade 1 late toxicities, 4 Grade 2 late toxicities, and no Grade 3 or higher late toxicities. Grade 2 toxicities included fibrosis (2), and pain (2). Two patients developed grade 1 asymptomatic nonpalpable fat necrosis both diagnosed at 12 months after radiation treatments. The most common grade 1 late toxicities were breast pain (14), hyperpigmentation (8), fibrosis (10), and fatigue (5). Physicians scored cosmesis excellent or good 70/73 (95.8%), 58/60 (96.7%), 36/36 (100%),17/17(100%) respectively at baseline, 12 months, 24 months, and 36months post SBRT, while patients scored the same periods 62/71 (83.7%), 53/59 (89.8%), 33/36 (91.6%), 17/18 (94.4%). There have been no reports of disease recurrences.Results at 24-month median follow-up, of our dose escalated stereotactic partial breast 5 fraction regimen, has low acute and late toxicity, while maintaining high proportion of excellent/good cosmetic outcomes. Continued analysis of all cohorts is in progress.gov identifier is NCT03581136." @default.
- W4387208883 created "2023-09-30" @default.
- W4387208883 creator A5000962617 @default.
- W4387208883 creator A5011166582 @default.
- W4387208883 creator A5023838874 @default.
- W4387208883 creator A5026905234 @default.
- W4387208883 creator A5040407093 @default.
- W4387208883 creator A5043616313 @default.
- W4387208883 creator A5045561467 @default.
- W4387208883 creator A5046229568 @default.
- W4387208883 creator A5050220404 @default.
- W4387208883 creator A5050391090 @default.
- W4387208883 creator A5054097443 @default.
- W4387208883 creator A5056023437 @default.
- W4387208883 creator A5056388685 @default.
- W4387208883 creator A5059684522 @default.
- W4387208883 creator A5064620272 @default.
- W4387208883 creator A5065389810 @default.
- W4387208883 creator A5068359755 @default.
- W4387208883 creator A5070254208 @default.
- W4387208883 creator A5071400654 @default.
- W4387208883 creator A5073447045 @default.
- W4387208883 date "2023-10-01" @default.
- W4387208883 modified "2023-10-04" @default.
- W4387208883 title "Multi-Institutional Phase II Trial Using Dose Escalated Five Fraction Stereotactic Partial Breast Irradiation (S-PBI) with GammaPodTM for Early-Stage Breast Cancer" @default.
- W4387208883 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1082" @default.
- W4387208883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784857" @default.
- W4387208883 hasPublicationYear "2023" @default.
- W4387208883 type Work @default.
- W4387208883 citedByCount "0" @default.
- W4387208883 crossrefType "journal-article" @default.
- W4387208883 hasAuthorship W4387208883A5000962617 @default.
- W4387208883 hasAuthorship W4387208883A5011166582 @default.
- W4387208883 hasAuthorship W4387208883A5023838874 @default.
- W4387208883 hasAuthorship W4387208883A5026905234 @default.
- W4387208883 hasAuthorship W4387208883A5040407093 @default.
- W4387208883 hasAuthorship W4387208883A5043616313 @default.
- W4387208883 hasAuthorship W4387208883A5045561467 @default.
- W4387208883 hasAuthorship W4387208883A5046229568 @default.
- W4387208883 hasAuthorship W4387208883A5050220404 @default.
- W4387208883 hasAuthorship W4387208883A5050391090 @default.
- W4387208883 hasAuthorship W4387208883A5054097443 @default.
- W4387208883 hasAuthorship W4387208883A5056023437 @default.
- W4387208883 hasAuthorship W4387208883A5056388685 @default.
- W4387208883 hasAuthorship W4387208883A5059684522 @default.
- W4387208883 hasAuthorship W4387208883A5064620272 @default.
- W4387208883 hasAuthorship W4387208883A5065389810 @default.
- W4387208883 hasAuthorship W4387208883A5068359755 @default.
- W4387208883 hasAuthorship W4387208883A5070254208 @default.
- W4387208883 hasAuthorship W4387208883A5071400654 @default.
- W4387208883 hasAuthorship W4387208883A5073447045 @default.
- W4387208883 hasConcept C121608353 @default.
- W4387208883 hasConcept C126322002 @default.
- W4387208883 hasConcept C126838900 @default.
- W4387208883 hasConcept C141071460 @default.
- W4387208883 hasConcept C155806632 @default.
- W4387208883 hasConcept C168563851 @default.
- W4387208883 hasConcept C203092338 @default.
- W4387208883 hasConcept C2777757722 @default.
- W4387208883 hasConcept C2780943399 @default.
- W4387208883 hasConcept C2989005 @default.
- W4387208883 hasConcept C31760486 @default.
- W4387208883 hasConcept C509974204 @default.
- W4387208883 hasConcept C530470458 @default.
- W4387208883 hasConcept C535046627 @default.
- W4387208883 hasConcept C71924100 @default.
- W4387208883 hasConceptScore W4387208883C121608353 @default.
- W4387208883 hasConceptScore W4387208883C126322002 @default.
- W4387208883 hasConceptScore W4387208883C126838900 @default.
- W4387208883 hasConceptScore W4387208883C141071460 @default.
- W4387208883 hasConceptScore W4387208883C155806632 @default.
- W4387208883 hasConceptScore W4387208883C168563851 @default.
- W4387208883 hasConceptScore W4387208883C203092338 @default.
- W4387208883 hasConceptScore W4387208883C2777757722 @default.
- W4387208883 hasConceptScore W4387208883C2780943399 @default.
- W4387208883 hasConceptScore W4387208883C2989005 @default.
- W4387208883 hasConceptScore W4387208883C31760486 @default.
- W4387208883 hasConceptScore W4387208883C509974204 @default.
- W4387208883 hasConceptScore W4387208883C530470458 @default.
- W4387208883 hasConceptScore W4387208883C535046627 @default.
- W4387208883 hasConceptScore W4387208883C71924100 @default.
- W4387208883 hasIssue "2" @default.
- W4387208883 hasLocation W43872088831 @default.
- W4387208883 hasLocation W43872088832 @default.
- W4387208883 hasOpenAccess W4387208883 @default.
- W4387208883 hasPrimaryLocation W43872088831 @default.
- W4387208883 hasRelatedWork W2073937368 @default.
- W4387208883 hasRelatedWork W2106734666 @default.
- W4387208883 hasRelatedWork W2154093325 @default.
- W4387208883 hasRelatedWork W2402348016 @default.
- W4387208883 hasRelatedWork W2441734853 @default.
- W4387208883 hasRelatedWork W2466949046 @default.
- W4387208883 hasRelatedWork W3016928775 @default.
- W4387208883 hasRelatedWork W3029766897 @default.
- W4387208883 hasRelatedWork W4386294258 @default.
- W4387208883 hasRelatedWork W74687978 @default.
- W4387208883 hasVolume "117" @default.
- W4387208883 isParatext "false" @default.